Advertisement

How much will it hurt? Factors associated with pain experience in women undergoing medication abortion during the first trimester

      Abstract

      Objectives

      Few studies have investigated the features associated with pain levels during abortion. We aimed to investigate the risk factors for experiencing pain during medication abortion, focusing on women's psychological distress and anxiety levels.

      Study design

      We carried out this observational study at two centers in Bologna, Italy. We included women aged 18 years or more with a viable intrauterine pregnancy of up to 63 days of amenorrhea, who chose medication abortion. Women received 600 mg of Mifepristone orally and after 48 hours 400 mcg of buccal misoprostol, repeated after 3 hours according to local and regional medication abortion guidelines, as well as prophylactic analgesia. We evaluated the clinical characteristics which may represent risk factors for severe pain (Visual Analogue Scale ≥ 70) through a multivariate model.

      Results

      Two hundred forty-two patients were included in our analysis; 92 (38.0%) reported severe pain during medication abortion. Women with higher baseline anxiety levels (General Health Questionnaire 12 score ≥ 6 and General Anxiety Disorder 7 score ≥ 10) had a higher probability of experiencing pain with a Visual Analogue Scale ≥70 (OR = 3.33, 95% CI 1.43–7.76), as well as those who reported dysmenorrhea in the past year (OR = 6.30, 95% CI 2.66–14.91). Previous vaginal deliveries were inversely correlated with pain intensity (OR 0.26, 95% CI 0.14 – 0.50).

      Conclusions

      Increased baseline anxiety levels, dysmenorrhea and no previous vaginal deliveries are associated with severe pain in women undergoing medication abortion.

      Implications

      The identification of women at risk for severe pain based on clinical and historical factors as well as the definition of an adequate analgesic regimen may help to improve women's care and pain management during medication abortion.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kapp N
        • Eckersberger E
        • Lavelanet A
        • Rodriguez MI.
        Medical abortion in the late first trimester: A systematic review.
        Contraception. 2019; 99: 77-86https://doi.org/10.1016/j.contraception.2018.11.002
        • Chen MJ
        • Creinin MD.
        Mifepristone with buccal misoprostol for medical abortion: A systematic review.
        Obstet Gynecol. 2015; 126: 12-21https://doi.org/10.1097/AOG.0000000000000897
        • Cavet S
        • Fiala C
        • Scemama A
        • Partouche H.
        Assessment of pain during medical abortion with home use of misoprostol.
        Eur J Contracept Reprod Health. 2017; 22: 207-211https://doi.org/10.1080/13625187.2017.1315092
        • Saurel-Cubizolles M-J
        • Opatowski M
        • David P
        • Bardy F
        • Dunbavand A.
        Pain during medical abortion: A multicenter study in France.
        Eur J Obstet Gynecol Reprod Biol. 2015; 194: 212-217https://doi.org/10.1016/j.ejogrb.2015.09.025
        • Kemppainen V
        • Mentula M
        • Palkama V
        • Heikinheimo O.
        Pain during medical abortion in early pregnancy in teenage and adult women.
        Acta Obstet Gynecol Scand. 2020; 99: 1603-1610https://doi.org/10.1111/aogs.13920
        • von Hertzen H
        • Honkanen H
        • Piaggio G
        • Bartfai G
        • Erdenetungalag R
        • Gemzell-Danielsson K
        • et al.
        WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy.
        BJOG. 2003; 110: 808-818https://doi.org/10.1111/j.1471-0528.2003.02430.x
        • Penney G.
        Treatment of pain during medical abortion.
        Contraception. 2006; 74: 45-47https://doi.org/10.1016/j.contraception.2006.03.002
        • Livshits A
        • Machtinger R
        • David LB
        • Spira M
        • Moshe-Zahav A
        • Seidman DS.
        Ibuprofen and paracetamol for pain relief during medical abortion: A double-blind randomized controlled study.
        Fertil Steril. 2009; 91: 1877-1880https://doi.org/10.1016/j.fertnstert.2008.01.084
        • Avraham S
        • Gat I
        • Duvdevani N-R
        • Haas J
        • Frenkel Y
        • Seidman DS.
        Pre-emptive effect of ibuprofen versus placebo on pain relief and success rates of medical abortion: A double-blind, randomized, controlled study.
        Fertil Steril. 2012; 97: 612-615https://doi.org/10.1016/j.fertnstert.2011.12.041
      1. Safe abortion: Technical and policy guidance for health systems.
        2nd ed. World Health Organization, Geneva2012
        • Practice bulletin no
        143: Medical management of first-trimester abortion.
        Obstet Gynecol. 2014; 123: 676-692https://doi.org/10.1097/01.AOG.0000444454.67279.7d
        • Reynolds-Wright JJ
        • Woldetsadik MA
        • Morroni C
        • Cameron S
        Pain management for medical abortion before 14 weeks’ gestation.
        Cochrane Database Syst Rev. 2022; https://doi.org/10.1002/14651858.CD013525.pub2
        • Suhonen S
        • Tikka M
        • Kivinen S
        • Kauppila T.
        Pain during medical abortion: Predicting factors from gynecologic history and medical staff evaluation of severity.
        Contraception. 2011; 83: 357-361https://doi.org/10.1016/j.contraception.2010.08.006
        • Wiebe E.
        Pain control in medical abortion.
        Int J Gynaecol Obstet. 2001; 74: 275-280https://doi.org/10.1016/s0020-7292(01)00453-2
        • Westhoff C
        • Dasmahapatra R
        • Winikoff B
        • Clarke S.
        Predictors of analgesia use during supervised medical abortion. The Mifepristone Clinical Trials Group.
        Contraception. 2000; 61: 225-229https://doi.org/10.1016/s0010-7824(00)00090-1
        • Bélanger E
        • Melzack R
        • Lauzon P.
        Pain of first-trimester abortion: A study of psychosocial and medical predictors.
        Pain. 1989; 36: 339-350https://doi.org/10.1016/0304-3959(89)90094-8
        • Wells N.
        Pain and distress during abortion.
        Health Care Women Int. 1991; 12: 293-302https://doi.org/10.1080/07399339109515952
        • Goldberg DP
        • Gater R
        • Sartorius N
        • Ustun TB
        • Piccinelli M
        • Gureje O
        • et al.
        The validity of two versions of the GHQ in the WHO study of mental illness in general health care.
        Psychol Med. 1997; 27: 191-197https://doi.org/10.1017/s0033291796004242
        • Piccinelli M
        • Bisoffi G
        • Bon MG
        • Cunico L
        • Tansella M.
        Validity and test-retest reliability of the Italian version of the 12-item General Health Questionnaire in general practice: A comparison between three scoring methods.
        Compr Psychiatry. 1993; 34: 198-205https://doi.org/10.1016/0010-440x(93)90048-9
        • Spitzer RL
        • Kroenke K
        • Williams JBW
        • Löwe B.
        A brief measure for assessing generalized anxiety disorder: The GAD-7.
        Arch Intern Med. 2006; 166: 1092-1097https://doi.org/10.1001/archinte.166.10.1092
      2. Ministero della Salute, Linee di indirizzo sulla interruzione volontaria di gravidanza con mifepristone e prostaglandine 04/08/2020, https://www.salute.gov.it/imgs/C_17_pubblicazioni_3039_allegato.pdf.

        • Arena A
        • Orsini B
        • Degli Esposti E
        • Manzara F
        • Ambrosio M
        • Raimondo D
        • et al.
        The unbearable burden of endometriosis: Results from a large cohort about anxiety reduction during the first outpatient evaluation.
        J Psychosom Res. 2021; 147https://doi.org/10.1016/j.jpsychores.2021.110512
        • Fiala C
        • Cameron S
        • Bombas T
        • Parachini M
        • Agostini A
        • Lertxundi R
        • et al.
        Pain management for up to 9 weeks medical abortion - An international survey among abortion providers.
        Eur J Obstet Gynecol Reprod Biol. 2018; 225: 181-184https://doi.org/10.1016/j.ejogrb.2018.04.030
        • Laganà AS
        • La Rosa VL
        • Rapisarda AMC
        • Valenti G
        • Sapia F
        • Chiofalo B
        • et al.
        Anxiety and depression in patients with endometriosis: Impact and management challenges.
        Int J Womens Health. 2017; 9: 323-330https://doi.org/10.2147/IJWH.S119729
        • Hamoda H
        • Ashok PW
        • Flett GMM
        • Templeton A.
        Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation.
        BJOG. 2004; 111: 996-1000https://doi.org/10.1111/j.1471-0528.2004.00235.x
        • Westhoff C
        • Dasmahapatra R
        • Winikoff B
        • Clarke S.
        Predictors of analgesia use during supervised medical abortion.
        Contraception. 2000; 61: 225-229https://doi.org/10.1016/S0010-7824(00)00090-1